Identifying targets of dysregulated microRNAs (miRNAs) will enhance our understanding of how altered miRNA expression contributes to the malignant phenotype of breast cancer. The expression of miR-205 was reduced in four breast cancer cell lines compared to the normal-like epithelial cell line MCF10A and in tumor and metastatic tissues compared to adjacent benign breast tissue. Two predicted binding sites for miR-205 were identified in the 3' untranslated region of the high mobility group box 3 gene, HMGB3. Both dual-luciferase reporter assay and Western blotting confirmed that miR-205 binds to and regulates HMGB3. To further explore miR-205 targeting of HMGB3, WST-1 proliferation and in vitro invasion assays were performed in MDA-MB-231 and BT549 cells transiently transfected with precursor miR-205 oligonucleotide or HMGB3 small interfering RNA (siRNA). Both treatments reduced the proliferation and invasion of the cancer cells. The mRNA and protein levels of HMGB3 were higher in the tumor compared to adjacent benign specimens and there was an indirect correlation between the expression of HMGB3 mRNA and patient survival. Treatment of breast cancer cells with 5-Aza/TSA derepressed miR-205 and reduced HMGB3 mRNA while knockdown of the transcriptional repressor NRSF/REST, reduced miR-205 and increased HMGB3. In conclusion, regulation of HMGB3 by miR-205 reduced both proliferation and invasion of breast cancer cells. Our findings suggest that modulating miR-205 and/or targeting HMGB3 are potential therapies for advanced breast cancer.
Introduction
Breast cancer is the second most prevalent cancer in the USA and is the second most common cause of cancer-related death in this country [1] . It is estimated that 230,480 women will develop breast cancer in 2011 and 39,520 will die of this disease [2] . Like many cancers, breast cancer is a heterogeneous disease that differs molecularly, biologically and clinically. Breast cancer is commonly classified by the estrogen/progesterone (ER/PR) receptor status and the HER2 (ERBB2) amplification status. Breast cancers that are ER+ and or PR+ are treatable with hormonal therapies such as Tamoxifen, while patients having HER2 amplification respond to receptor tyrosine kinase inhibitors such as Trastuzumab. Triple-negative breast cancer (TNBC) is defined by the absence of ER and PR expression and HER2 amplification.
Approximately 10-20% of breast cancers are TNBC [3] . These patients have the worse prognosis because of the lack of effective targeted therapeutics [4] . The molecular basis for the TNBC is poorly understood. Successful treatments for TNBC may be possible once a more fundamental understanding of the aggressive phenotype is understood.
Expression of the microRNA, miR-205 is enriched in esophagus, trachea, breast, thymus and prostate tissues [5] . miR-205 is deregulated in many solid tumors; the expression is increased in some tumors while it is decreased in others. miR-205 was overexpressed in endometrial cancer [6] and non-small cell lung cancer [7] [8] [9] , while its' expression was downregulated in prostate cancer [10] , melanoma [11] [12] [13] and breast cancers [14, 15] . miR-205 is found exclusively in normal ducts and lobular myoepithelial cells of the breast but is significantly reduced in breast tumor tissues [15, 16] . The purported tumor suppressive functions of miR-205 in breast cancer is due to direct targeting of several oncogenes such as VEGFA, E2F1, E2F5, PKC epsilon and HER3 reviewed in 16 as well as attenuating epithelial to mesenchymal transition (EMT) by suppressing ZEB1 and ZEB2 [16] [17] [18] .
The intent of this study was to identify additional target genes for miR-205 that may be involved in the aggressive phenotype of TNBC. We identified HMGB3, a member of the high mobility group protein superfamily. We show that increased expression of HMGB3, due to reduced miR-205 expression, causes increased cell proliferation and in vitro invasion. Furthermore, breast cancer patients with increased HMGB3 expression have worse survival. These findings suggest that HMGB3 may serve as a biomarker and/or therapeutic target for breast cancer.
Materials and Methods

Ethics Statement
All research involving human specimens has been approved by the Ohio State University institutional review board.
Cell lines
MCF10A, MCF7, MDA-MB-231, MDA-MB-436 and BT549 cell lines were obtained from the American Type Culture Collection or were supplied by various investigators. MCF-10A cells stably expressing REST shRNA were generated as described [19] . MCF10A was cultured in DMEM and F-12 (1:1 ratio) containing 5% horse serum, hydrocortisone, human EGF, cholera toxin, insulin and 1% penicillin and streptomycin as described [19] . MCF7 and BT549 cell lines were maintained in MEM media supplemented with 10% FBS. MDA-MB-231 and MDA-MB-436 cells were cultured in DMEM with 10% FBS. All cell lines were cultured under standard conditions.
Tissue procurement
Snap frozen specimens of 33 human breast tissues were supplied by the Midwest division of the Cooperative Human Tissue Network (Columbus, OH). These included 11 matched pairs of tumor and normal adjacent tissue as well as metastatic disease. Clinical data on these tissues are provided in Table  S1 .
RNA extraction
Total RNA was extracted from the cell lines and tissues using Trizol (Invitrogen) and RNeasy mini kit (Qiagen), respectively, according to the manufacturer's instructions. Integrity of the RNA was measured by the Agilent Bioanlyzer; RIN (RNA integrity number) of 7 or higher were considered to have satisfactory integrity.
Real-time PCR
Mature miR-205-5p levels were assayed using TaqMan microRNA Reverse Transcription kit and TaqMan MicroRNA Assay (Applied Biosystems) per the manufacturer's instructions. Data were normalized to 18S rRNA and the relative gene expression was calculated using the comparative C T method as described [20] . Primers used in the qRT-PCR are provided in Table S2 .
Transient transfection assays
For HMGB3 functional studies, MDA-MB-231 and BT549 cell lines were lipofectamine 2000 transfected (Invitrogen) with HMGB3 siRNA or control siRNA (Dharmacon). Target identification studies were conducted by transfecting the same cell lines with precursor miR-205-5p mimic oligonucleotides (pre-miR-205-5p) or pre-miR negative control (Dharmacon). Transient transfection assays were conducted for 48 h with 100 nM of oligonucleotides.
miR-205 overexpressing stable cells
Partial length of the miR-205 primary precursor sequence was cloned and inserted into the pcDNA3.1(+) vector. MDA-MB-231 cells were transfected with the construct and selected using G418, Geneticin ® .
Lentiviral knockdown of REST in MCF7 cells
Stable REST knockdown in MCF7 cells was achieved using a Dharmacon SMARTvector lentiviral shRNA delivery system as per manufacturer's instructions. Briefly, cells were infected in the presence of 8 mg/mL polybrene at an MOI of 5 with virus expressing a non-targeting control or REST shRNA. Puromycin selection was initiated 48 h after infection and maintained during cell expansion. SMARTvector Lentiviral Particles (catalog # SH-042194-01-25) towards REST targeted the sequence GCAAACACCTCAATCGCCA, Non-Targeting SMARTvector shRNA Lentiviral particles (catalog # S-005000-01) were used as an infection control.
Luciferase reporter assay
Approximately 2.8 kbp of the HMGB3 3' untranslated region (3' UTR) containing two predicted miR-205 binding sites was PCR amplified and inserted downstream of the Renilla luciferase gene in the PsiCheck-2 plasmid (Promega). MDA-MB-231 cells were cotransfected with the HMGB3 PsiCheck-2 construct and 100 nM of pre-mir-205 or control oligo. After 48 h, the Renilla and Firefly luciferase activities were measured using the Dual-Luciferase Reporter Assay kit (Promega).
Western Blotting and antibodies
Protein was extracted from cell lines and human tissues using standard conditions. Anti-HMGB3 antibody (Abgent, # AJ1365) and anti-GAPDH (SC-32233, Santa Cruz Biotechnology).
WST-1 proliferation assay
Cells were plated in 96-well plate overnight and then transfected with 100 nM oligos. Following 96 h, WST-1 reagent (Roche) was added for 1.5 h and absorbance was measured using standard conditions. 
Matrigel invasion assay
Immunohistochemistry
Human breast tissues were fixed overnight in 10% formalin and then stained for HMGB3 using antibody (Abgent, # AJ1365) using standard techniques.
Drug treatment
In a 6-well plate, 2×10 5 cells were plated per well. Following an overnight incubation, the cells were exposed to 10 µM 5-Aza-2'-Deoxycytidine (5-Aza) (InSolution™ Millipore), 600 nM TSA (Trichostatin A, Sigma) or a combination of both. The cells were exposed to 5-Aza for 96 h; fresh drug was added after 48 h. For the combination treatment, TSA was added on the third day and cells were collected on fourth day.
Kaplan Meier survival plot
A disease free survival for breast cancer patients was analyzed as a function of HMGB3 gene expression using open access web resource G-DOC developed at Georgetown University Medical Center. See Methods S1 for detail.
Results
miR-205 expression in breast cell lines and tissues
The levels of miR-205 were measured in five breast cell lines. miR-205 was significantly reduced in BT549, MDA-MB-231 and MDA-MB-436 compared to the normal-like MCF10A breast cell line ( Figure 1A ). MCF7 is an ER/PR positive breast cancer cell line while BT549, MDA-MB-231 and MDA-MB-436 are TNBC cell lines. The levels of miR-205 were undetectable (C T > 37) in the TNBC cell lines. miR-205 was measured in 33 human breast tissues by qRT-PCR. There was a trend of reduced miR-205 expression when progressing from the normal adjacent tissue to non-metastatic and metastatic disease ( Figure 1B) . These results are in accordance with previous reports about the significant reduction of miR-205 in TNBC compared to other types of breast cancer [21, 22] .
Tumor suppressive role of miR-205
Functional studies of miR-205 were conducted in MDA-MB-231 and BT549 TNBC cell lines using both transient transfection of pre-miR-205 oligo and stable miR-205 over expression. Cell proliferation (Figure 2A 
miR-205 targets HMGB3
To investigate novel targets, we noted that TargetScan predicted two miR-205 binding sites in the 3' UTR of human HMGB3 ( Figure 3A) . Binding of miR-205 to the 3' UTR of HMGB3 was validated using luciferase reporter assays ( Figure  3B ). HMGB3 protein was reduced in MDA-MB-231 and BT549 cells transfected with pre-miR-205 oligo compared to control oligo ( Figure 3C ). In an effort to identify other predicted targets of miR-205, we measured their mRNA expression in MDA-MB-231 and BT549 cell lines following transfection of premiR-205 or pre-miRNA control oligos. Of the 23 genes measured by qRT-PCR, 6 (DOCK4, RAB6B, PLXNA4, RUNX2, HMGB1 and HMGB3) were significantly reduced in the miR-205 transfected cells ( Figure 3D ). These data confirm that the reduction in HMGB3 protein by miR-205 results from a decrease in the HMGB3 mRNA and identifies a number of potential miR-205 target genes.
Functional effects of miR-205/HMGB3 regulation in breast cancer
To determine functions of HMGB3 overexpression in breast cancer, we conducted WST-1 proliferation and in vitro invasion assays in breast cancer cell lines. We found a significant reduction of proliferation ( Figure 4A ) and invasion ( Figure 4B ) of MDA-MB-231 and BT549 cells treated with HMGB3 siRNA compared to scrambled control siRNA. Thus the effects of suppressing HMGB3 mRNA either by miR-205 oligo or HMGB3 siRNA are identical in these cell lines (Figures 2, 4) . The expression of HMGB3 mRNA was quantified in the 33 human breast tissues and was elevated in the metastatic group and in the breast tumors compared to unaffected adjacent benign tissue ( Figure 5A ). The HMGB3 protein levels were assayed in 5 matched pairs of the human breast tissues. HMGB3 was undetected in the normal adjacent tissue samples while abundantly present in the tumor tissue ( Figure 5B ). To identify tissue localization, we performed immunohistochemistry staining against HMGB3 protein and found that HMGB3 is localized in the glands and ducts of normal adjacent tissue while widespread in tumor tissue (Figure 5 C, D) . To determine if a correlation exists between HMGB3 expression and patient survival, we analyzed published breast cancer data sets. Three groups of patients were identified, those with an intermediate tumor levels of HMGB3 and those with increased or decreased HMGB3 expression in the tumors. Those patients with over expressed HMGB3 expression had the poorest survival (P<0.05). Patients with down regulated HMGB3 expression survived longer than those with intermediate expression, however the difference was not significant (p=0.09) ( Figure  5E ).
Relationship between miR-205, HMGB3 and EMT
Since miR-205 directly targets ZEB1 and ZEB2 in Madin Darby canine kidney cells [17] , reduced expression of miR-205 could maintain breast cancer cells in the mesenchymal state through ZEB1/ZEB2 inhibition of E-cadherin (CDH1). We validated these findings in the TNBC cell lines MDA-MB-231 and BT549. These cell lines are considered to be mesenchymal-like [23] . miR-205 transfection decreased the miR-205 Regulates HMGB3 in Breast Cancer PLOS ONE | www.plosone.orgprotein levels of the mesenchymal N-cadherin, vimentin and ZEB1 ( Figure S1 ). To relate HMGB3 to EMT, we measured epithelial and mesenchymal markers in MDA-MB-231 cells exposed to HMGB3 siRNA. Knocking down HMGB3 increased the expression of CDH1 while ZEB1 was essentially unchanged ( Figure S2 ). Thus HMGB3 promotes EMT, however it is not through inhibition of ZEB1 protein levels ( Figure S2 ).
Chromatin modifying agents attenuate HMGB3 levels through derepression of miR-205
Repression of miR-205 in prostate and breast cancer cell lines has been linked to promotor hypermethylation of the miR-205 host gene LOC642587 [24] . Also H3K9 deacetylation contributed to the miR-205 suppression in prostate cancer cell lines [24] . Attempts as miR-205 derepression in TNBC cells were done by treating MDA-MB-231 cells with 5-Aza/TSA. 5-Aza/TSA treatment increased the miR-205 expression by more than 2-fold ( Figure 6A ) and decreased HMGB3 mRNA nearly 2-fold ( Figure 6B ). Thus small molecule treatment of breast cancer may impact HMGB3 via derepression of miR-205.
Relationship between REST, miR-205 and HMGB3
REST/NRSF is transcriptional repressor of neuronal genes in non-neuronal tissues. A subset of breast cancers with reduced expression of REST (i.e. REST-less tumors) display a highly aggressive phenotype that includes poor prognosis and increased likelihood of disease recurrence within the first 3 years after diagnosis [19] . We examined the miR-205 expression in REST-less MCF-7 and MCF-10A cells (i.e. cells stably expressing REST shRNA). REST knockdown significantly reduced the miR-205 expression in MCF-7 but not MCF-10A cells ( Figure 7A, B) . Concomitantly, HMGB3 levels had a significant increase by REST knockdown in MCF-7 but not MCF-10A cells (Figure 7 C, D) . Thus, knockdown of REST enhanced the HMGB3 up-regulation, presumably through reduced miR-205, in the cancerous MCF-7 cells but had no Expression of the selected predicted oncogenic target genes of miR-205 was evaluated in both MDA-MB-231 and BT549 cells 48 h after transfection of either control oligonucleotides or pre-miR-205-5p. Expression levels were calculated relative to 18S rRNA and the data are expressed as fold-increase compared to cells treated with control oligo (assigned a value of "1"). effect on MCF-10A cells supporting the hypothesis that RESTless tumor cells display an aggressive phenotype [19] .
Discussion
The overall aim of this study is to support the tumor suppressor role of miR-205 in breast cancer and demonstrate that reintroduction or derepression of the miRNA in TNBC cell lines is beneficial. We report that the expression of HMGB3, a member of the high mobility group protein superfamily, is increased in advanced breast cancer. A link between HMGB3 and the invasive, metastatic phenotype has been made by demonstrating that HMGB3 mRNA levels are increased in metastatic breast cancers ( Figure 5A ), that knockdown of HMGB3 decreases in vitro invasiveness ( Figure 4B ) and patients with increased HMGB3 expression have poor survival ( Figure 5E ). Moreover, we link the up-regulation of HMGB3 in breast cancer to miR-205, a miRNA that has been shown here ( Figure 1 ) and in other studies [14] [15] [16] 18 ] to have reduced expression in breast cancer.
The HMG superfamily of DNA binding proteins recognize the HMG box, typically located in promoters. HMG proteins are referred to as architectural transcription factors [25] . The HMG family binds to and distorts DNA causing chromatin modification and facilitating either activating or repressing transcription factors to bind to the promoter [26] . There are two major subclasses of HMG proteins, HMGA and HMGB. There is structural resemblance between HMGB1, HMGB2 and HMGB3 which indicates similar biological functions for these proteins. Of the 4 HMGB proteins, HMGB1 has been the most heavily studied. HMGB1 is involved in many biological processes including DNA repair reviewed in 25. Previous studies have shown the oncogenic role of HMGB1 in cancer. When HMGB1 binds to its' receptor RAGE (receptor for advanced glycation end-products) it promotes tumor growth and metastasis [27] .
HMGB3 is present mainly in the bone marrow and is involved in hematopoietic stem cell renewal [28] . Recently, HMGB3 was reported to be a target for miR-206 and is involved in muscle regeneration [29] . It was among a group of embryonic stem cell-like transcriptional regulators overexpressed in poorly differentiated, high-grade tumors [30] . With the exception of the work by Ben-Porath, et al. [30] , we are unaware of any studies linking HMGB3 and breast cancer.
In summary, miR-205 is an important tumor suppressor in breast cancer. It has been shown to regulate a number of important oncogenic targets including ZEB1, VEGFA and HER3 reviewed in 16. Our data suggest that in addition to HMGB3, miR-205 may modulate a several additional targets such as PLXNA4 and RUNX2 ( Figure 3C ). It is possible Author Contributions
